A novel CpG-methylation-based nomogram predicts survival in colorectal cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. .
   PubMed Web of Science ®Google Scholar
• Guraya SY, Pattern S. Time of recurrent colorectal cancer after curative surgery. Clin Colorectal Cancer. 2019 Jun;18(2):e223–e228.
   PubMed Web of Science ®Google Scholar
• Lin HH, Wei NC, Chou TY, et al. Building personalized treatment plans for early-stage colorectal cancer patients. Oncotarget. 2017 Feb 21;8(8):13805–13817.
   PubMedGoogle Scholar
• Sahnane N, Magnoli F, Bernasconi B, et al. Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. Clin Epigenetics. 2015 Dec 21;7:131. .
   PubMed Web of Science ®Google Scholar
• Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006 Jul;38(7):787–793. .
   PubMed Web of Science ®Google Scholar
• Juo YY, Johnston FM, Zhang DY, et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014 Dec;25(12):2314–2327. .
   PubMed Web of Science ®Google Scholar
• Yi JM, Dhir M, Van Neste L, et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res. 2011 Mar 15;17(6):1535–1545.
   PubMed Web of Science ®Google Scholar
• Fu T, Pappou EP, Guzzetta AA, et al. IGFBP-3 gene methylation in primary tumor predicts recurrence of stage II colorectal cancers. Ann Surg. 2016 Feb;263(2):337–344. .
   PubMed Web of Science ®Google Scholar
• Perez-Carbonell L, Balaguer F, Toiyama Y, et al. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. PLoS One. 2014 Aug 15;9(8):e104285.
   PubMed Web of Science ®Google Scholar
• Gundert M, Edelmann D, Benner A, et al. Genome-wide DNA methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol classifier). Gut. 2019 Jan;68(1):101–110. .
   PubMed Web of Science ®Google Scholar
• Jia M, Zhang Y, Jansen L, et al. A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival. Clin Epigenetics. 2019 Jul 24;11(1):109.
   PubMedGoogle Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013 May;19(5):619–625. .
   PubMed Web of Science ®Google Scholar
• Suzuki H, Yamamoto E, Maruyama R, et al. Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun. 2014 Dec 5;455(1–2):35–42.
   PubMed Web of Science ®Google Scholar
• Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017 Nov;16(11):1155–1161.
   PubMed Web of Science ®Google Scholar
• Wei JH, Haddad A, Wu KJ, et al. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Nat Commun. 2015 Oct 30;6:8699. .
   PubMed Web of Science ®Google Scholar
• Guo W, Zhu L, Yu M, et al. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. Clin Epigenetics. 2018 Nov 16;10(1):142.
   PubMedGoogle Scholar
• Guo W, Zhu L, Zhu R, et al. A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma. Elife. 2019 Jun 6;8. DOI:10.7554/eLife.44310
   Web of Science ®Google Scholar
• Shen S, Wang G, Shi Q, et al. Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma. Clin Epigenetics. 2017 Aug 24;9:88. .
   PubMed Web of Science ®Google Scholar
• Cheung HH, Lee TL, Davis AJ, et al. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br J Cancer. 2010 Jan 19;102(2):419–427.
   PubMed Web of Science ®Google Scholar
• Cheung HH, Lee TL, Rennert OM, et al. DNA methylation of cancer genome. Birth Defects Res C Embryo Today. 2009 Dec;87(4):335–350. .
   PubMedGoogle Scholar
• Misawa K, Imai A, Mochizuki D, et al. Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis. Oncotarget. 2017 Sep 29;8(44):76318–76328.
   PubMedGoogle Scholar
• Liu CD, Slice LW, Balasubramaniam A, et al. Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels. Surgery. 1995 Aug;118(2):229–235. .
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang L, Liu L, et al. Rasip1 is a RUNX1 target gene and promotes migration of NSCLC cells. Cancer Manag Res. 2018 Oct 12;10:4537–4552. .
   PubMed Web of Science ®Google Scholar
• Wang Y, Ruan Z, Yu S, et al. A four-methylated mRNA signature-based risk score system predicts survival in patients with hepatocellular carcinoma. Aging (Albany NY). 2019 Jan 10;11(1):160–173.
   PubMedGoogle Scholar
• Sternberg CN. Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol. 2006 Aug 20;24(24):3819–3820.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013 Mar 20;31(9):1188–1195.
   PubMed Web of Science ®Google Scholar
• Honda M, Oba K, Akiyoshi T, et al. Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials. Oncotarget. 2017 Nov 17;8(58):99150–99160.
   PubMedGoogle Scholar
• Feng Y, Li Y, Cai S, et al. Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer. Cancer Manag Res. 2019 Aug 1;11:7279–7294. .
   PubMed Web of Science ®Google Scholar
• Kim C, Kim WR, Kim KY, et al. Predictive nomogram for recurrence of stage I colorectal cancer after curative resection. Clin Colorectal Cancer. 2018 Sep;17(3):e513–e518. .
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang D, Jin L, et al. Prognostic value of the combination of microsatellite instability and BRAF mutation in colorectal cancer. Cancer Manag Res. 2018 Sep 26;10:3911–3929. .
   PubMed Web of Science ®Google Scholar
• Murcia O, Juarez M, Rodriguez-Soler M, et al. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: prognostic implications and response to chemotherapy. PLoS One. 2018 Sep 6;13(9):e0203051.
   PubMed Web of Science ®Google Scholar
• Smeby J, Sveen A, Merok MA, et al. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann Oncol. 2018 May 1;29(5):1227–1234.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang D, Zhang H, et al. Genome-wide analysis of DNA methylation identifies two CpG sites for the early screening of colorectal cancer. Epigenomics. 2020 Jan;12(1):37–52. .
   PubMed Web of Science ®Google Scholar
• Cheng J, Wei D, Ji Y, et al. Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers. Genome Med. 2018 May 30;10(1):42.
   PubMedGoogle Scholar
• Linehan WM, Spellman PT, Ricketts CJ, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016 Jan 14;374(2):135–145.
   PubMed Web of Science ®Google Scholar